<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977090</url>
  </required_header>
  <id_info>
    <org_study_id>Gxplore-012-1</org_study_id>
    <nct_id>NCT03977090</nct_id>
  </id_info>
  <brief_title>Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase Ib Clinical Trial of Geptanolimab Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genor Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genor Biopharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, dose-escalating phase Ib clinical study to evaluate the safety&#xD;
      and tolerability of GB226 in combination with fruquintinib in the treatment of mCRC, evaluate&#xD;
      the pharmacokinetic characteristics of GB226 in combined therapy, evaluate immunogenicity of&#xD;
      GB226, and explore the antitumor activity of GB226 in combination with fruquintinib in the&#xD;
      treatment of mCRC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Adverse Event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limited Toxicity,DLT</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the safety of GB226 as defined by dose limited toxicity in patients with metastatic colorectal cancer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extended period recommended dose,RDE</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the safety of GB226 as defined by extended period recommended dose in patients with metastatic colorectal cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T max</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>T max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C max</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>C max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C ss,min</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>C ss,min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R C,trough</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>R C,trough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate, ORR</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the efficacy of GB226 as defined by objective response rate in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the efficacy of GB226 as defined by overall response rate, in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response, DOR</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the duration of response (DOR) of GB242 in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, PFS</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the efficacy of GB226 as defined by progression-free survival in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, OS</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the duration from the first administration to death because of any reason in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibody, ADA</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Antidrug antibody, ADA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>GB226+Fruquintinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab combined with Fruquintinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Geptanolimab Injection</intervention_name>
    <description>GB226 3mg/kg, q2w, iv.</description>
    <arm_group_label>GB226+Fruquintinib</arm_group_label>
    <other_name>Recombinant humanized anti-PD-1 monoclonal antibody injection</other_name>
    <other_name>Geptanolimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off</description>
    <arm_group_label>GB226+Fruquintinib</arm_group_label>
    <other_name>HMPL-013</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who meet the following criteria can be enrolled in this study:&#xD;
&#xD;
          1. Aged 18 to 75 years, males or females;&#xD;
&#xD;
          2. Understand the study procedures and contents, and voluntarily sign the written&#xD;
             informed consent form;&#xD;
&#xD;
          3. Patients with histologically/pathologically confirmed colorectal cancer;&#xD;
&#xD;
          4. Patients with metastatic colorectal cancer, who failed to respond to the previous&#xD;
             first-line treatment or above. Treatment failure refers to disease progression or&#xD;
             intolerable toxicity after ≥1 cycle of treatment, or relapse during adjuvant or&#xD;
             neoadjuvant chemotherapies period or within 6 months after the end of treatment;&#xD;
&#xD;
          5. ECOG score of 0-1;&#xD;
&#xD;
          6. Life expectancy≥3 months;&#xD;
&#xD;
          7. There is at least one measurable and evaluable tumor lesion (in accordance with&#xD;
             RECIST1.1 criteria);&#xD;
&#xD;
          8. Systemic chemotherapy, targeted therapies or other anti-tumor biotherapy (tumor&#xD;
             vaccine, cytokine or growth factor aimed at controlling tumor) are completed at least&#xD;
             4 weeks before the first dose of investigational product (the oral fluorouracil is&#xD;
             discontinued at least 2 weeks ago); systemic or local palliative radiotherapy is&#xD;
             completed at least 4 weeks ago; no anti-angiogenic small molecular target drugs are&#xD;
             previously received;&#xD;
&#xD;
          9. Systemic corticosteroids (prednisone &gt; 10mg/day or equivalent dose) is discontinued at&#xD;
             least 2 weeks before the use of the first investigational product;&#xD;
&#xD;
         10. The major surgery requiring general anesthesia must be completed at least 8 weeks&#xD;
             before the use of the first investigational product; surgery requiring local&#xD;
             anesthesia/epidural anesthesia must be completed at least 4 weeks before the use of&#xD;
             the first investigational product;&#xD;
&#xD;
         11. Routine blood tests require hemoglobin (HGB) ≥90g/L (no transfusion is allowed within&#xD;
             14 days before routine blood tests at baseline), neutrophil count (ANC)≥1.5×109/L&#xD;
             (received no supportive treatment with recombinant human granulocyte colony&#xD;
             stimulating factor within 14 days before routine blood tests at baseline), platelet&#xD;
             ≥100×109/L (received no supportive treatment such as recombinant human thrombopoietin&#xD;
             (TPO) or transfusion within 14 days before routine blood tests at baseline);&#xD;
&#xD;
         12. Serum creatinine ≤ 1.5×ULN or creatinine clearance ≥ 60 mL/min (calculated based on&#xD;
             Cockcroft-Gault formula), and urinary protein ˂ 2+ or ˂1.0g/L; For patients with&#xD;
             baseline urinary protein ≥ 2+ or ≥ 1.0g/L, quantitative test of 24h urinary protein&#xD;
             will be performed and will be enrolled only when the result ≤ 1.0g/L is obtained.&#xD;
&#xD;
         13. Total bilirubin ≤1.5×ULN (unless it is confirmed to have Gilbert's Syndrome),&#xD;
             aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (AST&#xD;
             and/or ALT≤5×ULN is allowed for patients with hepatic metastasis);&#xD;
&#xD;
         14. Thyroid function variables: thyroid-stimulating hormone (TSH) and free thyroxine&#xD;
             (FT3/FT4) are within the normal range; if TSH is not within the normal range, but&#xD;
             FT3/FT4 is within the normal range, the subjects can be enrolled.&#xD;
&#xD;
         15. The adverse reactions caused by the previous treatment should recover to grade 1 and&#xD;
             below before enrollment (except alopecia and ≤ grade 2 neurological toxicity caused by&#xD;
             chemotherapy drugs);&#xD;
&#xD;
         16. Female subjects who are confirmed not pregnant within 7 days before administration;&#xD;
             males or females should agree to adopt medically confirmed effective contraceptive&#xD;
             measures during the entire study period and within 6 months after the end of this&#xD;
             study.&#xD;
&#xD;
         17. Patients can receive follow-up visits as scheduled, well communicate with the&#xD;
             investigators and complete the study as required by the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any patient fulfilling any of the following exclusion criteria is excluded from this study:&#xD;
&#xD;
          1. Active central nervous system (CNS) metastasis, including symptomatic brain metastasis&#xD;
             or meningeal metastasis or spinal cord compression etc.; subjects with asymptomatic&#xD;
             brain metastasis (no progression within at least 4 weeks after radiotherapy and/or no&#xD;
             neurological symptom or sign after surgical resection, treatment with glucocorticoids,&#xD;
             antiepileptic drugs, anticonvulsants or mannitol is not necessary) can be enrolled;&#xD;
&#xD;
          2. Patients who previously had other malignant tumors (excluding cured cervical carcinoma&#xD;
             in situ and skin basal cell carcinoma) are not allowed to participate in the study&#xD;
             unless he/she completely relieved at least 2 years before enrollment and requires no&#xD;
             other treatment now or during the study period.&#xD;
&#xD;
          3. Medical history of active, known autoimmune diseases, including but not limited to&#xD;
             systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory&#xD;
             gastrointestinal disorders, Hashimoto's thyroiditis etc. The following should be&#xD;
             excluded: type I diabetes mellitus, hypothyroidism which can be controlled by hormone&#xD;
             replacement therapies only, skin diseases requiring no systemic treatment (e.g.,&#xD;
             vitiligo, psoriasis) and controlled celiac disease;&#xD;
&#xD;
          4. Patients who are previously treated with anti PD-1 antibody, anti PD-L1 antibody, anti&#xD;
             PD-L2 antibody or anti CTLA-4 antibody (or any other antibodies acting on T cell&#xD;
             co-stimulation or checkpoint pathway);&#xD;
&#xD;
          5. Uncontrolled hypertension ( systolic blood pressure ≥140mmHg and/or diastolic blood&#xD;
             pressure ≥90mmHg) or pulmonary arterial hypertension or unstable angina pectoris;&#xD;
             previous presence of myocardial infarction or received coronary artery bypass grafting&#xD;
             or coronary stent implantation within 6 months before administration; medical history&#xD;
             of chronic heart failure NYHA (New York Heart Association) class 3 and 4; clinically&#xD;
             significant valvular heart diseases; subjects with serious arrhythmia requiring&#xD;
             treatment, including QTc interval ≥450ms for males and ≥470ms for females (calculated&#xD;
             based on Fridericia formula); cerebrovascular accident (CVA) or transient ischemic&#xD;
             attack (TIA) within 12 months before administration;&#xD;
&#xD;
          6. Patients who have medical history of arterial thrombosis or deep vein thrombosis&#xD;
             within 6 months before the first dose of investigational product, or patients who have&#xD;
             evidence or medical history of bleeding tendency within 2 months before the first dose&#xD;
             of investigational product, regardless of severity; activated partial thromboplastin&#xD;
             time (APTT) or prothrombin time (PT) &gt;1.5×ULN;&#xD;
&#xD;
          7. The skin wounds, surgery site, trauma site, serious mucosal ulcer or facture are not&#xD;
             completely healed.&#xD;
&#xD;
          8. The imaging tests showing the evidence of tumor invasion to large vessels, including&#xD;
             tumors which are completely close to, surround or invade to internal cavity of large&#xD;
             vessels (e.g., pulmonary artery or superior vena cava);&#xD;
&#xD;
          9. Patients with dysphagia or known drug malabsorption;&#xD;
&#xD;
         10. Gastrointestinal disorder which may significantly affect absorption of oral drugs or&#xD;
             other conditions which may affect gastrointestinal hemorrhage or perforation (e.g.,&#xD;
             duodenal ulcer, bowel obstruction, acute Crohn's disease, ulcerative colitis,&#xD;
             resection of large area of stomach and small intestine etc.) at the discretion of the&#xD;
             investigators; Patients who have chronic Crohn's disease and ulcerative colitis&#xD;
             (excluding patients with resection of entire colon and rectum), even in non-active&#xD;
             stage, should be excluded. Patients with hereditary nonpolyposis colorectal cancer or&#xD;
             familial adenomatous polyposis syndrome; Previous medical history of intestinal&#xD;
             perforation, intestinal fistula, which is not cured after surgical treatment;&#xD;
&#xD;
         11. Subjects with current or previous interstitial lung pneumonia;&#xD;
&#xD;
         12. Uncontrolled pleural, peritoneal and pericardial effusion requiring repeated drainage&#xD;
             or showing significant symptoms;&#xD;
&#xD;
         13. Patients with active infection requiring systemic treatment; active pulmonary&#xD;
             tuberculosis (TB) infection;&#xD;
&#xD;
         14. Positive human immunodeficiency virus antibody (HIV-Ab); active syphilis; positive&#xD;
             hepatitis C antibody (HCV-Ab) and HCV-RNA&gt; the upper limit of normal of the test&#xD;
             units; positive hepatitis B surface antigen (HBsAg) and HBV-DNA copies &gt; the upper&#xD;
             limit of normal of the test units;&#xD;
&#xD;
         15. Patients with complications requiring treatment with immunosuppressive drugs or&#xD;
             systemic or local corticosteroids at the immunosuppressive doses (prednisone &gt;&#xD;
             10mg/day or equivalent dose of similar agents);&#xD;
&#xD;
         16. It is expected that live vaccines or attenuated vaccines are given 4 weeks before the&#xD;
             use of investigational drug, during treatment period or within 5 months after the last&#xD;
             dose;&#xD;
&#xD;
         17. Subjects who have medical history of drug addiction or drug abuse;&#xD;
&#xD;
         18. Lactating women (subjects who agree to stop breastfeeding during the study period can&#xD;
             be enrolled);&#xD;
&#xD;
         19. Patients who received other investigationsl drugs within 30 days before the use of&#xD;
             investigational drug or within 5 half-lives of other investigational drugs (whichever&#xD;
             is shorter) or used investigational medical device within 30 days;&#xD;
&#xD;
         20. Subjects who are known to be allergic to investigational product or any of its&#xD;
             excipients; subjects who are known to have medical history of allergic diseases;&#xD;
&#xD;
         21. Subjects who are considered unsuitable for participating in this study at the&#xD;
             discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuxian Bai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated tumor hospital of Harbin medical university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Yu, Master</last_name>
    <phone>86-010-85260820</phone>
    <email>shawn.yu@genorbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxian Bai, Doctor</last_name>
      <phone>86 13945095085</phone>
      <email>bai_yuxian@126.com</email>
    </contact>
    <investigator>
      <last_name>Yuxian Bai, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

